Vaximm GmbH

Vaximm Secures Potential $835M Deal with BCM Europe for Oral Cancer Immunotherapy Platform VXM01

- Vaximm has signed a non-binding term sheet with Swiss investor BCM Europe for a potential exclusive worldwide license of its oral cancer immunotherapy platform VXM01, with deal terms including $20 million upfront and up to $815 million in milestone payments. - The agreement includes a six-month exclusivity period for negotiations and due diligence, with BCME serving as a financial intermediary to fund development and secure partnerships with major pharmaceutical companies. - The collaboration allows Vaximm to retain full intellectual property ownership while accelerating global development and commercialization of VXM01, an oral T-cell immunotherapy designed to stimulate immune responses against cancer cells. - The partnership incorporates innovative blockchain-based royalty participation mechanisms using TAC tokens, reflecting modern financing models similar to those employed by Blackstone Life Sciences and Royalty Pharma.